Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales Soar
Eli Lilly has struggled to meet overwhelming demand for Zepbound and Mounjaro and is already working to see off competition from giants like Roche and Pfizer racing to bring their own obesity drugs to market.
Eli Lilly has struggled to meet overwhelming demand for Zepbound and Mounjaro and is already working to see off competition from giants like Roche and Pfizer racing to bring their own obesity drugs to market.
What's Your Reaction?
